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Abstract: Objective: Given recent concerns about cervical dysplasia with RA medications, we performed a literature 
review and a pooled analysis to examine the relative risk of cervical and vaginal cancers in RA. 
Methods: We conducted a literature search covering 2007- 2014. A pooled analysis was conducted: the total numbers of 
cancers expected and observed across all studies were respectively summed for different cancer types (cervical and 
vaginal/vulvar cancers). As some studies pooled vaginal and vulvar cancers together, we did not discern between the 
two for the purpose of this study. Using these pooled estimates, standardized incidence ratios (SIRs) were calculated, 
demonstrating the relative risk of the cancers in RA, versus the general population. 
Results: Our search strategy retrieved 13 papers. Our pooled SIR estimates were 0.82, 95% confidence interval, CI, 
0.73-0.92 for cervical cancer in RA and 1.04, 95% CI 0.80-1.34 for vaginal/vulvar cancer in RA. 
Conclusion: Our simple pooled analysis was consistent with a relatively lower cervical cancer risk in RA versus the 
general population, while the data did not establish if the risk of vaginal/vulvar cancer was different from the general 
population. Cervical cancer screening in RA will continue to be important, particularly as evolving treatment strategies 
may affect future risk. 
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INTRODUCTION 
Rheumatoid arthritis [RA] affects up to 1% of the 
developed world [1]. Malignancy is a major co-
morbidity associated with RA [2-4]. Moreover, women 
comprise the majority of RA patients, thus it is 
important to explore the occurrence of cervical and 
vaginal cancers in RA. Cervical cancer causes 
approximately a quarter of a million deaths worldwide 
every year in the general population [5] and cervical 
dysplasia is significantly increased in rheumatic 
disease populations like systemic lupus (SLE). Vaginal 
cancer is also increased in SLE, and like cervical 
cancer, is associated with human papillomavirus (HPV) 
infection [6]. We performed a literature review of peer-
reviewed articles evaluating vaginal and cervical 
cancers in RA, and a pooled analysis to examine the 
relative risk of these cancers in RA, compared to the 
general population. 
MATERIALS AND METHODS  
Eligibility Criteria 
For our study, we included original published peer-
reviewed prospective or retrospective observational 
cohort or nested case-control studies, documenting 
cervical and vaginal cancer incidence in adult RA 
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patients. The studies were only included if they 
provided standardized incidence ratios (SIR) or enough 
information to be able to calculate them, such as the 
observed and expected cancer incidence (based on 
general population cancer rates). We limited our 
analyses to English and French articles.  
Information Sources and Search Strategy  
We conducted a literature search using 
MEDLINE/PUBMED and EMBASE, covering January 
1st, 2007 to July 24th, 2014. The search terms used 
included: (Rheumatoid Arthritis or Inflammatory Arthritis 
or primary chronic polyarthritis or chronic progressive 
polyarthritis or rheumatic arthritis or rheumatic 
polyarthritis or chronic articular rheumatism) and 
(Cervical Cancer or Cervical Neoplasm or Cervical 
Carcinoma(s), Cervical Tumor or Cervical 
Adenocarcinoma(s) or Cervical Carcinogenesis or 
Cervical Sarcoma(s) or Vagina(-al) Cancer or Vagina(-
al) Tumor or Vagina(-al) Adenocarcinoma or Vagina(-
al) Carcinoma or Malignancy(-ies) and Vulva(r) Cancer 
or Vulva(r) Neoplasm or Vulva(r) Carcinoma or 
Endometrial Sarcoma or Vulva(r) Tumor or Vulva(r) 
Malignancy) and (cohort analysis/ or longitudinal study/ 
or prospective study/ or follow up/ or cohort$.tw. or 
followup.mp. or case control study/ or hospital based 
case control study/ or population based case control 
study/ or cancer epidemiology/ or (cancer adj3 
epidemiolog*).mp. or observational study/ or 
observational method/) [7]. 
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We also reviewed the bibliographies and references 
of the included studies and published reviews, to 
identify any additional papers of relevance. We 
excluded studies that only looked at a subset of RA 
patients, such as cohorts formed by exposure to 
specific treatments. 
After the initial search, we screened the titles and 
abstracts to identify all potentially relevant studies. 
Then we then reviewed the remaining full texts to 
confirm which articles met our inclusion criteria. 
We then abstracted the following data: author, study 
year, publication year, method of cancer 
ascertainment, location of study, average follow up 
years, average age groups sample size, study design, 
observed events, expected events, SIR, and 
confidence intervals. A primary simple pooled analysis 
was conducted: the total numbers of cancers expected 
and observed across all studies were respectively 
summed for each of the different cancer types (cervical 
and vaginal/vulvar cancers). As some studies pooled 
vaginal and vulvar cancers together, we did not discern 
between the two for this study. Using the total number 
of observed and pooled expected cancers across all 
studies, we then formed a pooled standardized 
incidence ratio (SIR) which is the ratio of the number of 
observed cancers divided by the number expected. We 
generated 95% confidence intervals for the SIRs, by 
treating the number of observed cancers as a Poisson-
distributed variable, then finding its related interval from 
published tables [8].  
RESULTS 
Our search strategy retrieved 1,698 research 
papers. After removing duplicates, 1,474 remained. We 
excluded 1,227 upon review of the titles and abstracts, 
which did not meet our inclusion criteria. Thus, we were 
left with 247 research papers of interest. 
Of these, ten papers did not study RA subjects. 
Seven papers were excluded because they did not 
examine malignancy, but rather cancer mortality. 
Fifteen papers only examined specific RA 
subpopulations and so their subjects did not represent 
the generalized RA population. Thirty papers were 
excluded because they either studied cancer 
prevalence (not incidence) or did not provide expected 
cancer incidence or enough information to estimate 
this. Fifty-two papers were excluded because they 
were not original observational studies, and seventy-
two papers did not look at malignancy at all. Forty-six 
papers were also excluded because they did not 
examine the cancers of interest, but looked only at 
other cancers associated with RA such as lung, kidney, 
liver neoplasms etc. 
In the end, from the years 1993 to 2014, there were 
fifteen cohort studies that looked at the incidence of at 
least one of the cancers of interest [9-23]. Askling et 
al., 2005 [10], Hemminiki et al., 2008 [14] and 
Hemminiki et al., 2012 [15] used data from the Swedish 
National Inpatient Register and the Swedish Cancer 
Register. To avoid data overlap, we included only 
Hemminiki et al., 2012 [15] who used data between 
1964 and 2008 and seemed to be the most inclusive of 
all three papers. Both Huang et al., 2014 [16] and Chen 
et al., 2011 [11] also used the same source and 
overlapping period to collect their data, more 
specifically the National Health Insurance Research 
Database. As a consequence, we only included Huang 
et al., 2014 [16], for cervical cancers, who examined 
patients for a similar (but longer) period from 1996 to 
2008. However, for vaginal cancers, we included Chen 
et al. because Huang et al. did not examine vaginal 
cancers and so there was no overlap. 
Thus thirteen research papers were included in our 
final cervical cancer analysis and three in our 
vaginal/vulvar cancer analysis. These studied a total of 
188,597 women with RA in the context of cervical 
cancer, which were observed for a total of 1,588,982 
person-years and 94,581 women with RA in the context 
of vaginal/vulvar cancer for 471,611 person-years. 
Overall, 308 cervical cancers and 63 vaginal cancers 
were observed (see Tables 1 and 2). The pooled SIRs 
were 0.82 (95% CI: 0.73-0.92) for cervical cancer and 
1.04 (95% CI: 0.80-1.34) for vaginal/vulvar cancer.  
DISCUSSION 
Cervical and vaginal cancers are two important 
gynecological malignancies and it is essential to track 
the various patterns associated with these cancers to 
implement surveillance and prevention strategies. 
Statistical research in cervical cancer is complex 
because cervical, vulvar and vaginal cancers are 
related to HPV infection [14, 15, 24, 25]. In other 
autoimmune rheumatic diseases such as systemic 
lupus (SLE), there is a concern that HPV clearance is 
impaired or delayed, resulting in a persistent carriage 
of HPV, and risk of cervical dysplasia/neoplasia and 
vaginal/vulvar cancers [26, 27]. An increased risk of 
cervical dysplasia is well documented in SLE, along 
with an increased risk of vaginal/vulvar cancers 
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Table 1: Studies Assessing Observed and Expected Cervical Cancers in Women with Rheumatoid Arthritis 
Study Cancer Ascertainment Method Comparator Country Female N Mean 
Person-
Years 
Follow Up 
Female 
Person-
Years 
Observed Expected Standardiz
ed 
Incidence 
Ratio 
95% 
Confiden
ce 
Intervals 
Huang et al. 2014 ICD-9-CM codes 
from the National Health 
Insurance Research Databases 
and Registry of Catastrophic 
Illness Database 
general Taiwanese 
population 
Taiwan 23680 7.4 175232 60 74.0 0.81 0.63-1.04 
Hemminki et al. 
2012 
ICD-9 codes 
from the Swedish Hospital 
Discharge Register and the 
Nation-Wide Swedish Cancer 
Registry 
patients not 
hospitalized for 
any autoimmune 
diseases 
Sweden 38881 18.8 731954 105 93.8 1.12 0.92-1.36 
Yamada et al. 
2011 
IORRA cohort patient self-reports general Japanese 
population 
Japan 6189 3.4 21211 4 2.9 1.36 0.37-3.49 
Parikh-Patel et al. 
2009 
ICD-9 codes from California 
OSHPD patient hospital discharge 
data set 
and 
California Cancer Registry data 
set 
general California 
population 
USA 65236 4.8 313133 47 110.0 0.43 0.31-0.57 
Abasolo et al. 
2008 
EMECAR RA cohort; Cancer was 
ascertained from the medical 
records and verified with the 
patient during the study visit. 
GLOBOCAN 
database general 
population of Spain 
Spain 568 2.7 1538 1 0.2 4.10* 0.10-
22.70 
Wolfe and 
Michaud 2007 
US National Data Bank for 
Rheumatic Diseases longitudinal 
study of RA outcomes semiannual 
questionnaires 
Population cancer 
rates from the US 
Surveillance, 
Epidemiology, and 
End-Results 
database 
USA 10818 4.5 48582 4 5.0 0.80 0.40-1.90 
Thomas et al. 
2000 
ICD-9; ICD-10 codes hospital in-
patient records and the Scottish 
Cancer Registry 
national cancer 
incidence rates of 
the Scotland 
general population 
Scotland 19543 5.7 113333 26 29.2 0.89 0.58-1.31 
Cibere et al. 1997 University of Saskatchewan 
Rheumatic Disease Unit semi-
annual mailing of the Stanford 
Health Assessment Questionnaire 
and patient follow-up and 
Provincial Cancer Registry 
province of 
Saskatchewan 
population 
Canada 577.5 17.4 10049 1 2.0 0.49 0.06-2.76 
Mellemkjaer et al. 
1996 
ICD-8 codes of Danish Hospital 
Discharge Register and Danish 
Cancer Registry 
Danish population Denmark 14647 7.0 102529 40 36.9 1.10 0.80-1.50 
Morimoto et al. 
1995 
RA patients living in Osaka 
prefecture and treated at the 
Center for Adult Diseases were 
matched against the files of the 
Osaka Cancer Registry 
Osaka general 
population 
Japan 524 6.1 3196 3 1.4 2.15 0.43-6.27 
Gridley et al. 
1993 
ICD-7 and ICD-8 codes in 
Swedish Hospital Inpatient 
Register and National Swedish 
Cancer Registry 
Uppsala Health 
Care Region 
cancer incidence 
rates 
Sweden 7933.0 8.6 68224 17 18.9 0.90 0.50-1.40 
TOTAL    188597 7.86 1588982 308 374.37 0.82 0.73-0.92 
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Table 2: Studies Assessing Observed and Expected Vaginal/Vulvar Cancers in Women with Rheumatoid Arthritis 
Study Cancer 
Ascertainment 
method 
Comparator Country Female N Mean 
Person-
Years 
Follow Up 
Female 
Person-
Years 
Observed Expected Standardized 
Incidence 
Ratio 
95% 
Confidence 
Intervals 
Chen et al. 2011 ICD-9 codes 
from the Registry 
of Catastrophic 
Illness Database 
general Taiwanese 
population 
Taiwan 18527 5.9 109309 5 2.96 1.69 1.54-1.84 
Parikh-Patel et al. 
2009 
ICD-9 codes from 
California OSHPD 
patient hospital 
discharge data set 
and 
California Cancer 
Registry data set 
general California 
population 
USA 65236 4.8 313133 56 56.6 0.99 0.75-1.29 
Wolfe and 
Michaud 2007 
US National Data 
Bank for 
Rheumatic 
Diseases 
longitudinal study 
of RA outcomes 
semiannual 
questionnaires 
Population cancer 
rates from the US 
Surveillance, 
Epidemiology, and 
End-Results 
USA 10818 4.55 49169 2 0.74 2.7 0.80-8.60 
TOTAL    94581 5.08 471611 63 60.3 1.04 0.80-1.34 
 
[28, 29]. However, there is very little data to indicate 
whether cervical cancer itself is increased in SLE 
compared to the general population; in part, the 
difficulty is likely because this is a fairly rare cancer in 
absolute terms  
In RA, at least one study has found that women with 
RA, in general, are at elevated risk of cervical dysplasia 
and that this risk appeared to be augmented with the 
use of tumor necrosis factor (TNF) inhibitors [30]. 
Earlier studies found an increased risk of HPV infection 
in RA patients treated with disease-modifying agents 
(DMARDs) [12, 31] and with prednisone [31]. 
In any pooled analysis, the results are only as good 
as the data within the primary reports. A potential 
limitation is that several studies relied at least in part on 
patient self-reports, although attempts were often made 
to confirm those cancers, using medical records. 
Consequently, some cases could have been missed, or 
alternatively over-reported. However, excluding from 
our analysis, the studies that employed self-report to 
identify cancers did not appreciably alter the total SIR 
or its confidence intervals. Chen et al. also disclosed 
that in their paper RA itself could have been 
misclassified due to the use of an administrative 
database. This is a limitation present with most of the 
studies we examined but does not necessarily explain 
why the SIR estimate for cervical cancer was below the 
null value. 
As is shown in Table 1, although for most studies 
the SIR for cervical cancer in RA were close or below 
1.0, in some cases the point estimate was well above 
1, but in all cases the confidence intervals were 
relatively wide and included the possibility of a 
decreased cervical cancer risk in RA compared to the 
age-matched general population rates. As noted 
above, in some cases the means of cancer 
ascertainment varied between studies, while the 
general population comparator appeared to be 
reasonably homogeneous. In some cases, the 
demographics were clearly different (for example some 
studies arose from purely Asian populations, such as 
Taiwan or Japan, while others arose from largely 
Caucasian populations, such as Sweden) but this did 
not translate to clear differences in the SIR point 
estimates. 
One might expect patients with RA to be more 
closely followed than the general population, so pre-
malignant lesions may be detected and dealt with very 
promptly. Was that the case, this would presumably 
lead to a lower than expected cervical cancer risk in 
RA. However, so far, RA patients have been shown to 
have similar cancer screening to the general population 
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and so the issue of surveillance bias may be less likely 
[32]. Still, in general, it is felt that any women who are 
immunosuppressed may be at increased risk for 
cervical dysplasia, thus women with RA should 
continue to undergo cancer screening as per regional 
guidelines. Our recent review of the issue in SLE found 
that in this population, most authors recommend 
adherence to general population screening measures, 
particularly cervical screening [33]. 
In summary, we were unable to establish if the rate 
of vaginal/vulvar cancers in RA was any different from 
the general population. The suggestion of lower 
incidence of cervical cancers versus the general 
population is unexplained. Cervical cancer screening in 
RA should still be adhered to, particularly as evolving 
treatment strategies may affect future risk. 
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